Chardan analyst Geulah Livshits lowered the firm’s price target on Metagenomi (MGX) to $7 from $11 and keeps a Buy rating on the shares after the company reported Q3 results, announced the appointment of Dr. Jian Irish to CEO, and shared updated preclinical data on lead in vivo insertion program MGX-001 in hemophilia A. The firm updated its model for Q3 financials and removed the majority of platform value from the model in light of prioritization.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGX:
- Metagenomi Announces Positive Preclinical Data for MGX-001
- Metagenomi CEO Brian Thomas to transition out of role, Jian Irish to succeed
- Metagenomi reports Q3 EPS (55c), consensus (53c)
- Metagenomi reports new dose range finding data from MGX-001 hemophilia A program
- Metagenomi reduces workforce by 25%